title: Cardiac sarcoidosis.
abstract: Cardiac involvement is undeniably one of the most challenging issues in sarcoidosis. Although autopsy studies reveal heart lesions in 20 to 30% of sarcoid patients, fewer than 5% suffer from clinical disease. Cardiac sarcoidosis (CS) has a predilection for the myocardium, but the pericardium and endocardium may also be affected. CS manifestations are various and most frequently include the following: (1) aberrations of atrioventricular or intraventricular conduction, either silent or symptomatic; (2) ventricular arrhythmias; (3) subacute congestive heart failure; and (4) sudden death. CS must be detected in all sarcoid patients by means of detailed medical history, physical examination, and resting electrocardiogram (ECG) at first evaluation and during follow-up. In patients with suspected CS, further investigations are aimed at evaluating diagnosis and cardiac consequences. Unfortunately, no gold standard exists that would allow CS diagnosis with a level of confidence. Endomyocardial biopsy is an invasive procedure that lacks sensitivity. Patients need, at a minimum, specialized cardiologic advice, echocardiography, and 24-hour ambulatory ECG. Other diagnostic tools include thallium, technetium, and gallium scintigraphy, and more recently, 18F-fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance (CMR). The respective role of these new imaging tools in the diagnostic approach remains to be defined. CMR has the advantage of not exposing patients to radiation, but it is not feasible in those with cardiac devices. In Western countries, heart involvement accounts for 13 to 25% of sarcoidosis-related deaths, and it is the leading cause of mortality in Japan. The main prognostic indicators are New York Heart Association functional class, left ventricular enlargement, and sustained ventricular tachycardia. Treatment is based on systemic corticosteroids with an initial dose between 30 mg/day and 1 mg/kg/day (which is usually maintained for at least 24 months), specific cardiologic agents, and the placement of a pacemaker or implantable cardiac defibrillator in case of an atrioventricular block or severe intractable ventricular arrhythmias. Cardiac transplantation is exceptionally required.
authors.affiliation: Service de Pneumologie, Hôpital Avicenne, Assistance Publique - Hôpitaux de Paris, Bobigny, France. hilario.nunes@avc.aphp.fr
authors.forename: Hilario
authors.initials: H
authors.lastname: Nunes
authors.forename: Olivia
authors.initials: O
authors.lastname: Freynet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Naggara
authors.forename: Michael
authors.initials: M
authors.lastname: Soussan
authors.forename: Pierre
authors.initials: P
authors.lastname: Weinman
authors.forename: Benoît
authors.initials: B
authors.lastname: Diebold
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Brillet
authors.forename: Dominique
authors.initials: D
authors.lastname: Valeyre
mesh_terms: D001706:Biopsy; D002317:Cardiovascular Agents / Q000627:therapeutic use; D004452:Echocardiography / Q000379:methods; D015716:Electrocardiography, Ambulatory; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006331:Heart Diseases / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D016027:Heart Transplantation; D006801:Humans; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography / Q000379:methods; D012507:Sarcoidosis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*
chemical_list: D002317:Cardiovascular Agents; D005938:Glucocorticoids